GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen, as the pharma ends work on another potential ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the ...

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...